Moderna's flu vaccine may not fuel a further recovery for the hard-hit COVID-19-affected stock.

Cancer was a key focus, with programs targeting solid tumors, Lynch syndrome, melanoma, and non-small cell lung cancer.

Moderna Inc. Chief Executive Officer Stephane Bancel said he sees the pending launch of a planned flu vaccine as a chance to ...

Moderna (MRNA) stock jumps on Science Day pipeline update and FDA flu vaccine vote; see key catalysts, technical levels, and ...

Moderna just received fantastic news.

The endorsement of an advisory committee positions Moderna to complete a dramatic turnaround for a shot the FDA declined to ...

Moderna (MRNA) has been struggling to shake one label for years: Covid winner. That label helped to make the company famous, ...

VWAP resistance, R&D wins, Q1 revenue surge, and mRNA-1010 risks missed flu contracts—the rating shifts to Sell. Click for an ...

Alex Hogan is STAT’s senior multimedia producer and host of STATus Report, STAT’s weekly video series. You can follow him on Bluesky. The story of the biotech company Moderna almost reads like a ...

The company's pending vaccine approvals could help the stock continue its rise.

Moderna Inc.’s influenza vaccine made with mRNA technology was recommended for approval by outside advisers to the US Food ...

June 16 (Reuters) - Moderna appointed a new chief commercial officer and widened its president's role to oversee certain ...